In neuroblastoma (BE(2)-C) and pancreatic cancer cells (MiaPaca-2), the SIRT2 inhibitor SAL was shown to diminish the N-Myc and c-Myc protein levels, but not mRNA expression (Liu et al., 2013[20]). Here, MYCN is linked to pancreatic neoplasm.